Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals
Evidence-based recommendations on bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse in adults
Evidence-based recommendations on cyanoacrylate glue occlusion for varicose veins. This involves injecting medical glue (cyanoacrylate) into a vein to close it
Evidence-based recommendations on MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy in adults and children. This involves inserting a
Evidence-based recommendations on selective internal radiation therapy for unresectable colorectal metastases in the liver in adults. This involves injecting
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2
Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy
Evidence-based recommendations on open prenatal repair of open neural tube defects in the fetus
Evidence-based recommendations on fetoscopic prenatal repair of open neural tube defects in the fetus
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654
Evidence-based recommendations on reducing the risk of Creutzfeldt–Jakob disease (CJD) transmission from surgical instruments used for interventional procedures
Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal
Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis (RRMS) in adults
Evidence-based recommendations on balloon dilation for chronic eustachian tube dysfunction in adults and children
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older
Evidence-based recommendations on gammaCore for cluster headache
Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2
Evidence-based recommendations on rucaparib (Rubraca) for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults
NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults
NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease
Evidence-based recommendations on midcarpal hemiarthroplasty (using a metal implant to create an artificial wrist joint) for wrist arthritis in adults
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults
Evidence-based recommendations on high-intensity focused ultrasound for glaucoma in adults. This involves using high-intensity ultrasound to destroy a small
Evidence-based recommendations on bioprosthetic plug insertion for anal fistula in adults. This involves putting a plug into the fistula and stitching it in
NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma
NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma
This guidance has been updated and replaced by NICE guideline NG199.
Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites
Evidence-based recommendations on implant insertion for prominent ears in children, young people and adults
This guidance has been updated and replaced by NICE technology appraisal guidance 770.
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma (SEA; elevated levels of eosinophils in blood) in adults
In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.
Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer that
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults